Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves NDA of oral allergy drug
Xyzal tablets received FDA approval on May 25, 2007 and both formulations are now approved for use in adults and children 6 years and older. Studies in allergic
Xyzal tablets received FDA approval on May 25, 2007 and both formulations are now approved for use in adults and children 6 years and older. Studies in allergic
Bon Secours will be implementing CrossWalk to connect its hospitals’s supply item files and chargemasters, thus enabling a process by which mark-up strategies can be modeled before implementation
The $1 million payment has been triggered with the significant progress made in the first stage of evaluation of the licensed proteins. This evaluation strongly supported the potential
The first patients in a 600-patient Phase II study have been enrolled. The study will investigate the effects of Lu AA34893 on the depressive episodes in bipolar disorder
Trinity Health will be using Capsule’s DataCaptor Connectivity Suite to automate the capture of patient data from bedside devices, including GE Monitors from the Unity network. DataCaptor collects
The Phase III ESCAPE (Evaluation of Sorafenib, Carboplatin And Paclitaxel Efficacy in NSCLC) trial evaluated Nexavar when administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in
MRX-4 was nasally administered as a single dose once a week for four consecutive weeks. The first administration was given without a nasal allergen challenge (NAC) while the
The license represents an extension of the existing license of all the GVK Bio Target and Drug databases. The GVK Bio databases contain over 3.2 million compounds manually
This trial is currently being conducted in the US by a clinical research organization, specializing in the conductance of Phase I studies. The drug is orally administered to
Fast track is a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet medical need. Once a